Access To Publish Data From Thiarabine Combination Trial

Acces has declared that new Thiarabine preclinical efficacy data will shortly be published, demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either agents alone.

In one colorectal cancer model, 66% of mice were cured of their tumors. The publication which will appear in the journal Cancer Chemotherapy and Pharmacology, was based on work conducted by Access’ collaborators at the Southern Research Institute.

In the study, thiarabine, clofarabine, and their combinations were tested in five tumor models.

David Nowotnik, Senior Vice President of Research and Development, said: In all cases, thiarabine demonstrated superior tumor growth inhibition than clofarabine when the agents were used alone.

But, in the combination of these two agents, efficacy was dramatically superior to the use of either agent alone. Tumor regression and cures were observed in several models including colorectal cancer and leukemia. The combination of agents proved to be effective even when used at low doses, indicating a potential for effective treatment with a reduced side-effect profile, he added.